Get notified of page updates
Sign Up for FORCE
Newsletters
The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT04115306
Study Contact Information:
For more information about the study, visit https://phoenixmd.ca/clinical-trials.
Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer
About the Study
PMD-026 is a study for people who have been diagnosed with triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC. NOTE: This study is no longer enrolling.
This Study is Open To:
NOTE: This study is no longer enrolling.
This Study is Not Open To:
NOTE: This study is no longer enrolling.